Johnson & Johnson vs SAP SE — how do they compare? Johnson & Johnson trades at $260.6 (market cap $626.09B), while SAP SE trades at $202.94 (market cap $240.81B). The key difference: Johnson & Johnson is far larger — about 2.6× SAP SE's market cap, and Johnson & Johnson pays the higher dividend (2.06%). Which is the better fit depends on your goals.
| JNJ | SAP | |
|---|---|---|
Market Cap | $626.09B | $240.81B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $280.46 |
52-Week Low | $172.78 | $146.38 |
Enterprise Value | $654.37B | $239.52B |
Dividend Yield | 2.06% | 1.4% |
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
SAP stock trades at $203.07, down 2.63% today, with a bullish technical signal from moving averages but bearish oscillators. The company reported strong Q2 2026 revenue growth driven by cloud demand, though it missed EPS estimates. Fundamentals show robust profitability with a 20.41% net income margin and rising cash flow from operations to $9.16B in 2025. Recent news highlights AI and cloud strategy advancements, with shares reacting positively to analyst upgrades and earnings resilience.
The outlook is cautiously optimistic, with a consensus price target of $209.67 offering modest upside. Investment opportunities lie in SAP's cloud transition and AI integration, but risks include execution challenges, margin pressure from investments, and competitive threats. The stock's valuation at a P/E of 27.16 may limit near-term gains if growth slows.
Trailing returns across standard periods
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →